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Layered double hydroxide nanostructures and
nanocomposites for biomedical applications
Li Yan,c Sevil Gonca,b Guangyu Zhu, e Wenjun Zhang d and
Xianfeng Chen *ab
Layered double hydroxide (LDH) nanostructures and related nanocomposites have attracted significant
interest in biomedical applications including cancer therapy, bioimaging and antibacterial treatment.
These materials hold great advantages including low cost and facile preparation, convenient drug
loading, high drug incorporation capacity, good biocompatibility, efficient intracellular uptake and
endosome/lysosome escape, and natural biodegradability in an acidic environment. In this review, we
summarize the development of three types of LDH nanostructures including pristine LDH, surface
modified LDH, and LDH nanocomposites for a range of biomedical applications. The advantages and
disadvantages of LDH nanostructures and insights into the future development are also discussed.
1. Introduction
Layered double hydroxides (LDH) are a type of anionic clay with
the formula generally expressed as [M1x
2+ Mx
3+(OH)2] [A
n]x/n
zH2O, where divalent cations M
2+ are Mg2+, Fe2+, or Co2+;
trivalent cations M3+ are Al3+, Fe3+, or Gd3+; and non-framework
and exchangeable anions An are Cl, CO3
2, NO3
, etc.1–5
(Fig. 1). LDH are positively charged because M2+ anions are
partially substituted by M3+. LDH nanostructures have been
widely utilized for many applications, including energy, health-
care, catalysis and optics. This review will focus on the bio-
medical applications of LDH nanostructures and nanocomposites.
Herein, we classify LDH nanostructures into 3 categories including
pristine LDH nanostructures, surface modified LDH nanostructures
including nanoparticles and recently reported nanosheets, and LDH
nanocomposites. These LDHnanomaterials are useful for a range of
biomedical applications (Fig. 2). For example: (1) –OH groups make
LDH sensitive to an acid environment and degrade easily in the
biological environment to release loaded therapeutic molecules for
bio-responsive drug delivery and (2) the positive charge of LDH
allows thematerial to effectively interact with negatively charged cell
membranes for efficient intracellular delivery. Due to the broad
applications, LDH nanostructures are increasingly attractive and the
synthesis, characterization and applications of LDHhave undergone
rapid development during the last decade.6–11 The number of
Fig. 1 Schematic illustration of LDH structure and chemical components6
(reproduced from The Royal Society of Chemistry with permission). (a)
LDH nanoparticles7 (reproduced from Macmillan Publishers Limited with
permission), (b) LDH nanosheets7 (reproduced from Macmillan Publishers
Limited with permission), (c–f) LDH nanocomposites (reproduced from
American Chemical Society, Springer, Elsevier and The Royal Society of
Chemistry with permission).8–11
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publications on LDH in both general and specific biomedical
applications is increasing every year.
Pristine LDH nanoparticles were initially introduced for
drug and gene delivery for cancer chemotherapy and then
LDH nanostructures with different morphologies and geome-
tries were developed for a wider range of applications. During
this journey, to satisfy the requirements of advanced drug
delivery systems and different biomedical applications, surface
modified LDH nanostructures and LDH based nanocomposites
have also been explored. In this review, we summarize and
highlight the most important development of these three types
of LDH nanostructures for biomedical applications, discuss
about their advantages and disadvantages, and also provide our
insights into the challenges and future applications of LDH
nanomaterials.
2. Pristine LDH nanostructures for
drug and gene delivery
Biological barriers in the human beings can effectively restrict
hazardous agents and thus protect them from harmful diseases. As
one of the most common biological barriers, the cell membrane can
isolate, protect and regulate cells from the external environment.12–16
However, the fine and sophisticated structure of the cell membrane
unavoidably and strictly prohibits the transport of drugs and genes
into the cytoplasm and nucleus, resulting in minimal or even
negligible delivery efficiency.17 To address this problem, methods
including biological,18–22 chemical,23–27 and physical approaches28–33
have been extensively developed. Among these technologies, nano-
materials show great potential to permeate the cell membrane and
greatly increase drug delivery efficiency with low toxicity.34–41 Besides
drug delivery application, nanostructures are also broadly used
for other biomedical applications such as bioimaging, sensing,
and separating protein/harmful agents.42–46
2.1 Cancer therapy and drug delivery
Pristine LDH nanoparticles were first introduced in the 2000s
as a nonviral vector for biomolecule and deoxyribonucleic acid
(DNA) delivery by Choy and co-workers.47 In 2004, Choy et al.
reported that pristine LDH nanoparticles could load negatively
charged drug molecules for cancer therapy.48 Methotrexate
(MTX) was loaded into the interlayer space of LDH nano-
particles by mixing LDH with MTX at room temperature for
3 days through ion-exchange by replacing the NO3 ions. After
drug loading, the interlayer space of LDH nanoparticles
expanded from 8.4 to 19.9 Å, but the structure and function of
MTX and LDH nanoparticles were maintained without detect-
able change. The in vitro cell line test results showed that MTX-
LDH nanoparticles were effective sooner than MTX alone. With
24 hours co-incubation of cell lines and drugs, the viability of
Fig. 2 The types, drug loading strategies and applications of layered double hydroxide (LDH) nanostructures.
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the cancer cells treated with MTX remained over 90%; in
comparison, the viability of cells in the MTX-LDH treated group
dropped to below 80%. Attractively, MTX-LDH nanoparticles
effectively suppressed the proliferation of SaOS-2 cancer cells
(osteosarcoma, human), but showed a negligible effect on normal
cells (fibroblasts, human tendon). This work first demonstrated
that LDH nanoparticles could act as a biocompatible non-viral
vector for enhanced anti-cancer drug delivery.
The effectiveness of using LDH nanoparticles for drug delivery
and the attractive cancer cell killing specificity were later demon-
strated also in cisplatin prodrug delivery.49 In terms of drug
delivery effectiveness, disuccinatocisplatin (DSCP)-loaded LDH
nanoparticles exhibited dramatically higher cytotoxicity than
the free prodrug: the IC50 value of DSCP against A2780 cancer
cells was 1.75  0.20 mM, while the value was 0.34  0.17 mM for
LDH–Pt(IV) (LDH nanoparticles loaded with DSCP), indicating a
5-fold reduction of the IC50 value (Table 1). With regard to
cell specificity, LDH-Pt(IV) nanoparticles were significantly less
effective towards the tested normal cells (NIH3T3, HS27 and
BEAS-2B). For example, the IC50 values of cisplatin and DSCP
were 5.1  0.8 and 30  2 mM, respectively, while the value of
LDH–Pt(IV) was over 50 mM. These comparisons indicate that
DSCP-loaded LDH nanoparticles are very effective in killing
cancer cells, but relatively safe to healthy cells, which is ideal
for anticancer drug design. To explain the cancer cell targeting
specificity, the platinum content of cells was investigated after
incubation with DSCP and DSCP-LDH. It was found that LDH-
Pt(IV) could deliver 10-fold more drug to cells compared to
DSCP alone.
Following the test in cell lines, Choi et al. studied MTX-LDH
nanoparticles with an average diameter of 130 nm for in vivo
cancer therapy.50 Free MTX and MTX-LDH nanoparticles were
intraperitoneally injected into two groups of mice bearing
orthotopic human breast tumors. In the biodistribution analysis,
it was discovered that the tumor–liver drug accumulation ratio of
the MTX-LDH nanoparticle treated group was 6 times higher
than that of the MTX-treated group. In line with this LDH
nanoparticle enabled targeted delivery of MTX to the tumor,
the antitumor efficacy of the nanoparticle treated group was
significantly improved, indicated by 81.4% and 74.3% reductions
of tumor volumes compared with that in the phosphate buffered
saline (PBS) and free MTX group, respectively. This also shows
that the efficacy of free drug is very low.
Besides cancer chemotherapy, LDH nanoparticles were also
utilized as a photosensitizer vector for photodynamic therapy.
Duan and co-workers reported that the incorporation of zinc
phthalocyanine (ZnPc) into the gallery of LDH nanoparticles
resulted in high singlet oxygen production efficiency, improved
photostability, good biocompatibility and low cytotoxicity.51 The
in vitro test showed that a low dosage of ZnPc (10 mg mL1) caused
potent damage to HepG2 cells with less than 15% viability. The
in vivo investigation demonstrated that LDH nanoparticles
effectively inhibited tumor growth with an ultra-low dose of
0.3 mg kg1 and a low optical fluence rate of 54 J cm2.
Recently, Mei et al. reported two-dimensional LDH monolayers
with a diameter of 50 nm and a thickness of 0.8 nm for controlled
loading and targeted delivery for cancer therapy.52 In this research,
monolayered LDH nanosheets were loaded with the anti-
cancer drug doxorubicin (DOX) with a high loading capacity
of 3.6 mg mg1 (DOX/LDH). The fabricated nanovectors, which
could be further conjugated with the targeting agent folic acid,
exhibited selective high toxicity towards cancer cells (KB cancer
cells) and reduced toxicity to normal cells.52 Gao et al. developed
a supramolecular photosensitizer (isophthalic acid/LDH nano-
hybrids) that could be activated by a near-infrared laser for
efficient two-photon photodynamic therapy.53 Upon 808 nm laser
irradiation, this LDH based hybrid demonstrated significantly
increased tissue penetration depth and was capable of killing
cancer cells inside the tumor.53
Beyond cancer therapy, LDH nanoparticles have also been
applied to many other applications.54 For example, to overcome
the limitation of the short half-life of the anticoagulant drug
low molecular weight heparin (LMWH), LMWH-LDH nano-
particles were fabricated via a co-precipitation method (adding
drug simultaneously during the LDH nanoparticle preparation
process, instead of preparing LDH nanoparticles first followed
by drug loading via ion-exchange).55 The in vitro release test
indicated a biphasic and sustainable release profile of LMWH-
LDH nanoparticles in pH 7.4 PBS solution at 37 1C. The liberation
of the anticoagulant drug was 20% in the first 12 hours, followed
by a further 20% release in the following 108 hours. The same
group also found that LMWH-LDH nanoparticles had the
potential to treat restenosis of an artery that occurs after surgically
removing atherosclerotic lesions and restoring blood flow.56 Rest-
enosis is the recurrence of blood vessel narrowing. LMWH-LDH
nanoparticles were tested on rat vascular smooth muscle cells
(SMC): LMWH-LDH nanoparticles showed a higher ability to inhibit
the migration and proliferation of SMC, with over 60% reduction of
SMC compared with the control group (only growth medium). The
enhanced efficacy of LMWH-LDH nanoparticles was explained as
Table 1 IC50 values of cisplatin, DSCP, LDH-Pt(IV), and LDH in different cell lines
49 (reproduced from The Royal Society of Chemistry with permission)
Cell type Cell line Cisplatin [mM] DSCP [mM] LDH-Pt(IV) [mM] LDH [mg L1]
Cancer A549 5.0  0.4 9.8  0.2 0.84  0.28 4150
Cancer A2780 0.45  0.1 1.8  0.2 0.34  0.17 4150
Cancer NCI-H1299 3.3  0.4 4.2  0.7 0.71  0.07 N.D.
Cancer MCF-7 17  1 425 1.9  0.6 N.D.
Cancer HCT116 3.7  0.5 12  1 0.49  0.03 N.D.
Normal NIH3T3 5.1  0.8 30  2 450 4150
Normal HS27 7.6  0.7 35  2 450 N.D.
Normal BEAS-2B 2.7  0.2 4.6  0.9 23  1 45
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due to the higher cellular uptake through the endocytic pathway,
quick escape from late endosomes/lysosomes, and effectively
inhibited mitogen-activated protein kinase (MAPK) signal transduc-
tion over a prolonged period of time57 (Fig. 3). LMWH delivery by
LDH vectors was further improved by using antibody-targeted LDH
nanoparticles for atherosclerosis.58 In the system, an antibody
(H93.7C.1D2/48; 1D2) was covalently conjugated to LMWH to form
the 1D2–LMWH complex. Subsequently, this 1D2–LMWH complex
was loaded into LDH nanoparticles via electrostatic interaction.
The results showed that this nanodrug delivery system could be
effectively transported to the arterial injury site with the aid of a
targeting antibody, consequently achieving the sustained release
of LMWH and resulting in minimized luminal loss and reduced
thrombotic occlusion in a rat model of arterial injury.
Additionally, LDH nanoparticles were employed as an adjuvant
to promote Th1 or Th2 dominant immune responses for
vaccination purpose.59 LDH nanoparticles were conjugated with
a toll-like receptor ligand CpG, leading to significantly enhanced
antibody response and a switch from Th2 towards Th1 response.
On Day 21, LDH delivery induced significantly higher IgG2a
antibody response than a standard commercial adjuvant Alum.
Moreover, the animal test showed that immunization of mice with
CpG-OVA-conjugated LDH nanoparticles before challenging with
OVA-expressing B16/F10 tumor cells retarded tumor growth and
prolonged the survival of tumor-bearing mice.59 Furthermore,
LDH nanoparticles loaded with the antigen Intimin b showed
significantly enhanced uptake by antigen-presenting cells, pro-
moting immune responses against infections by diarrheagenic
E. coli.60 LDH nanoparticles with Intimin b induced strong
antibody- and cell-mediated immune responses, which main-
tained for at least four months in the mouse model with no
changes in the histopathology of the animal organs.
Very recently, LDH nanoparticles were used for in vivo anti-
fatigue by incorporating folic acid.61 LDH-folic acid constructs
were fabricated via a co-precipitation method. It was found that
the constructs were able to prolong the forced swimming time
of the tested mice by 32% and 51% in comparison with the folic
acid group and the control, with negligible cytotoxicity to
normal cells. The forced swimming test was used to evaluate
the mice’s physical endurance capacity: reduced susceptibility
to fatigue was correlated with longer swimming times.56 Inter-
estingly, it was also found that LDH-folic acid had an obvious
effect on decreasing blood urea nitrogen and blood lactic acid,
and increasing muscle and hepatic glycogen levels. These
results indicated that LDH-folic acid effectively protected the
body from fatigue. Wang et al. reported dexamethasone sodium
phosphate (Dexa)-LDH nanoparticles for asthma treatment.62
In the allergic asthma rat model, this nanostructure effectively
reduced inflammatory cells (macrophages, eosinophils and
neutrophils) in the bronchoalveolar lavage (BAL) fluid, inhibited
the increase of T-helper-2-type cytokines, and suppressed airway
hyperresponsiveness.
For biomedical applications, it is essential for materials to
have minimal toxicity. To know this, the bio-safety of LDH nano-
particles was investigated in vivo.63 The study demonstrated that,
when LDH nanoparticles were intravenously injected to Sprague
Dawley rats at a dose of below 200 mg kg1, no obvious systemic
side-effect could be observed in clinical chemistry and histo-
pathology. This study confirmed the excellent biocompatibility of
LDH nanoparticles and indicated their promising applications in
biomedicine. The effectiveness and biocompatibility of LDH nano-
structures can be controlled through various designs. When tested
in mammalian cell lines,59 it was found LDH nanostructures were
rapidly uptaken by cells, and the shape had an influence on their
Fig. 3 Schematic diagram showing the proposed intracellular trafficking of LMWH-LDH nanoparticles in SMC. Both LMWH (A) and LMWH-LDH (B) are
internalized by SMC via endocytosis; however, LMWH-LDH has the capacity of ‘endosomal escape’ preventing the degradation of LMWH in lysosomal
compartments. LMWH-LDH and LMWH act to inhibit the MAPK pathway.57 (Reproduced from Elsevier with permission.)
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distribution in cells: rod-like LDH could target the nucleus, while
sheet-like LDH were retained in the cytoplasm. The intracellular
uptake process of LDH nanostructures was assumed to be
happening through a number of steps including quick adhesion
of the material to the cell membrane, clathrin-mediated endo-
cytosis to enter cells, and endosomal/lysosomal escape to the
cytoplasm. For rod-like LDH nanoparticles, there is an extra step
of nuclear translocation64 (Fig. 4). Recently, Senapati et al.
loaded a hydrophobic anticancer drug, raloxifene hydrochloride
(RH), into a series of Mg–Al LDH nanoparticles with various
charge density anions through the ion exchange technique for
controlled drug delivery.65 Through this, the release profiles of
RH could be tuned from fast to sustained release by altering the
exchangeable anions: nitrate incorporated LDH nanoparticles
allowed interaction with the loaded drug and consequently led to
sustained drug delivery; in comparison, the phosphate incorporated
LDH–drug system exhibited fast release of drug due to loose
interactions between LDH nanoparticles and drug molecules. The
in vivo study suggested that the LDH–drug system with slow release
profiles was a safer nanovector for cancer therapy.
2.2 Gene delivery
Gene therapy has attracted scientists and clinicians for treating
diseases using therapeutic nuclei acids, such as DNA, small
interfering RNA (siRNA) andmicroRNA (miRNA).66–73 For example,
siRNA showed great potential for cellular therapy of neuro-
degenerative disorders,74–76 cancers77–79 or infectious diseases.80,81
However, the success of gene therapy was hindered by limitations
such as ease of degradation, low efficiency of delivery, and high
toxicity in systemic transport. To solve these problems, LDH
nanoparticles have been used for gene delivery since 2000s. This
material could protect the gene from degradation and also enhance
intracellular delivery efficacy.82 Li et al. discovered that 20 nm LDH
nanoparticles could effectively enter both the cytoplasm and cellular
nucleus, while large (180 nm) ones only located in the cytoplasm.83
Therefore, 20 nm LDH nanoparticles were used to deliver the
pEGFP-N1 DNA plasmid to transfect NSC 34 cells with minimal
cell death. Although LDH nanoparticles could be used for gene
delivery, the transfection efficiency was found to be generally low
because of the large size of DNA.84 For this reason, LDH nano-
particles would be more suitable for siRNA delivery.85,86 In one
study, LDH-siRNA displayed greatly enhanced intracellular delivery
of siRNA to mammalian cells86 and cortical neurons.85 The intra-
cellular uptake of LDH-siRNA was demonstrated to be through
clathrin-mediated endocytosis. As shown in Fig. 5a, in the absence
of chlorpromazine (a clathrin-mediated endocytosis inhibitor),
strong fluorescence signals (siRNA duplex was covalently coupled
to 6FAM fluorophore at the 50 end) were observed in cells at 40 min
after incubation (Fig. 5a–i). In great contrast, in the presence of
chlorpromazine, significantly diminished fluorescence signals were
found within the neuronal cytoplasm. These observations indicated
that clathrin-mediated endocytosis played an important role in LDH
internalization.86
LDH nanoparticles also show promise for topical application
of RNA interference for sustained protection against plant
viruses.87 Pathogen-specific double-stranded RNA (dsRNA) can
protect plants from viral infection, but its instability limits the
application. To address this problem, dsRNA was loaded on
LDH nanoparticles. The results demonstrated that the stability
of dsRNA could be improved and the dsRNA was able to be
slowly released even 30 days after spraying on plant leaves. Very
attractively, a single spray of dsRNA loaded on LDH nano-
particles on plant leaves enabled virus protection for at least
20 days (Fig. 5b and c).
2.3 Co-delivery of drugs/genes and bioimaging
Simple delivery of one kind of drug is sometimes not able to
satisfy the requirement of an advanced drug delivery system.
Taking cancer therapy as an example, multiple drugs are often
used to have different targets such as targeting both nucleus
DNA and mitochondrial membranes, allowing much improved
therapeutic efficacy and alleviated drug resistance.88,89 Therefore,
combination therapy (delivery of two or more types of drugs) has
received increasing attention.90–92
For this, LDH nanoparticles have been developed to simulta-
neously transport two types of cancer treatment agents to improve
cancer therapy and overcome drug resistance.93 In one example,
LDH nanoparticles were used as a vector to deliver the anticancer
drug 5-Fluorouracil (5-Fu) and Allstars Cell Death siRNA (CD-siRNA)
for potent cancer treatment.94 The experiment outcomes proved
Fig. 4 Schematic illustration of LDH-FITC nanoparticle endocytosis and
cellular trafficking. (A) TEM image of LDH-FITC nanoparticles; (B) CHO
cells after addition of LDH-FITC nanoparticles to the cell culture medium;
(C) pumping protons into the endosome to facilitate acidification for
subsequent proteolysis of nutrients, followed by an influx of chloride ions;
(D) acid-driven dissolution of LDH-FITC nanoparticles in the late endo-
some to buffer acidification and release many ions; (E) entrance of water
molecules to the endosome due to an increase in ionic strength, leading to
osmotic swelling and endosome burst which releases LDH-FITC nano-
particles into the cytoplasm. Step (I): Adhesion of LDH-FITC nanoparticles
to the cell membrane; (II) clathrin-mediated endocytosis; (III) endosomal
changes; (IV) nuclear localization of LDH-FITC; (V) cytoplasmic distribution
of LDH-FITC; (VI) lysosomal pathway; (VII) unspecific uptake through
macropinocytosis; (VIII and IX) caveolae-mediated endocytosis; (X) micro-
tubule directing the freed LDH-FITC nanoparticles to the nucleus.64
(Reproduced from Elsevier with permission.)
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that the combined chemotherapy and gene therapy significantly
enhanced the cytotoxicity of 5-Fu in three cancer cell lines (MCF-7,
U2OS and HCT-116). In addition, LDH nanoparticles were reported
to simultaneously load a Pt(IV) prodrug and a p53 activator.95 It was
discovered that the in vitro anticancer activity of cisplatin in p53-wild
type cells was dramatically enhanced. The introduction of active p53
protein promoted apoptotic pathways initiated by platinum drugs,
thereby substantially increasing the efficacy of the cisplatin prodrug
(Fig. 6). Wang et al. co-loaded Pt(IV) prodrugs and the Chlorin e6
(Ce6) photosensitizer into LDH nanoparticles to overcome the drug
resistance of cisplatin.96 Ce6 photosensitizer and Pt(IV) prodrugs
loaded LDH nanoparticles exhibited a synergistic effect in
killing cancer cells, and particularly, were highly active towards
cisplatin-resistant cells, showing up to 190-fold increased efficiency
in comparison with cisplatin alone. It is well known that the failure
of cancer chemotherapy could be attributed to the escape of cancer
cells from the immune system. In order to tackle this problem,
Wang et al. fabricated a cisplatin-loaded immunochemotherapeutic
LDH nanohybrid that bears an immune checkpoint inhibitor for
enhanced cancer therapy97 (Fig. 7). In the study, LDH nanoparticles
were co-loaded with the first line chemotherapy drug cisplatin and
the immune checkpoint inhibitor indoleamine-2,3-dioxygenase
(IDO) inhibitor. The in vitro cervical cancer cell study revealed
improved cellular accumulation, increased binding of Pt to DNA
and higher apoptosis. The IDO inhibitor could inhibit indoleamine-
2,3-dioxygenase and activate T cells, thus ultimately boosting the
anti-tumor performance of the nanohybrid.97
Most recently, LDH has been fabricated as a multifunctional
drug carrier for theranostic applications.98–101 For instance, Li
et al. reported pH-ultrasensitive Mn(II)-containing LDH nano-
particles with superb longitudinal relaxivity (9.48 mM1 s1 at pH
5.0 and 6.82 mm1 s1 at pH 7.0 vs. 1.16 mm1 s1 at pH 7.4) for
magnetic resonance imaging (MRI).102 A two-step method was
utilized to synthesize Mn-LDH: Mg3Al-LDH nanoparticles were
first obtained through a co-precipitation method followed by
isomorphic substitution of partial number of Mg2+ with Mn2+
ions (Fig. 8). The in vivo study revealed that Mn-LDH nano-
particles exhibited clear MRI for tumor tissues in mice for up
to 2 days post intravenous injection, and also these nanoparticles
were very promising for cancer diagnosis and treatment. Further-
more, Peng et al. prepared Gd3+-doped monolayered LDH
nanosheets with controlled composition and morphology,100
Fig. 5 (a) siRNA-LDH nanoparticles are internalized by clathrin-mediated endocytosis. Confocal images show a large number of brightly fluorescent
puncta throughout the cytoplasm of neurons (arrowheads) and along their extended neurites (arrows) when incubated with siRNAeHtte6FAMeLDH
complexes (i). In the presence of chlorpromazine (CPZ) (an inhibitor of clathrin-mediated endocytosis) few 6FAM-positive vesicles are seen in the
neurons (iii). However, faint 6FAM-positive puncta are visible at the plasma membrane (arrows). Panels (ii) and (iv) are the corresponding bright field
images of panels (i) and (iii), respectively.86 (Reproduced from Elsevier with permission.) (b and c) Images showing the extent of necrotic lesions on N.
tabacum cv. Xanthi leaves challenged with PMMoV 5 days post spray treatment (b) and 20 days post spray treatment (c). *p o 0.05, **p o 0.01 and
***po 0.001 are significant using the Kruskal–Wallis test with a post-hoc Nemenyi test for multiple comparisons between samples compared with LDH.
Data represent mean  s.e.m.87 (Reproduced from Macmillan Publishers Limited with permission.)
Fig. 6 Schematic illustration of co-delivery of a Pt(IV) prodrug and a p53
activator to enhance the anticancer activity of cisplatin95 (reproduced from
The Royal Society of Chemistry with permission).
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and loaded the nanosheets with DOX (chemotherapy drug) and
indocyanine green (photodynamic and photothermal agent)
with a high loading content of 797.36% and an encapsulation
efficiency of 99.67%. The in vitro and in vivo study demonstrated
trimode (chemotherapy, photodynamic and photothermal therapy)
synergetic anticancer activity with good biocompatibility. Mean-
while, Gd3+-doped monolayered LDH nanosheets could be
utilized as dual mode imaging (near-infrared fluorescence and
magnetic resonance imaging) agents to visualize the tumor site
with minimal invasion.100 This example well demonstrates the
powerful function for drug delivery and integrated treatment
and diagnosis.
3. Surface modified LDH for
biomedical applications
Although LDH nanoparticles are widely used as a vector
for enhanced drug and gene delivery, the vast majority of
studies have been based on as-prepared pristine (non-surface
modified) LDH structures. However, these pristine nano-
particles often suffer from problems of instability in in vivo
applications due to the lack of surface stabilization. Moreover,
besides increasing the stability of LDH nanoparticles, surface
modification plays an extremely important role in using nano-
materials for biomedical applications.103–107 Firstly, surface
modification allows convenient attachment of targeting ligands
to nanostructures for targeted delivery. Secondly, surface modifica-
tion renders nanomaterials flexibility in drug loading and
versatile functionalities. Thirdly, surface modification is very
important for enhancing nanomaterials’ cellular uptake, stability,
and biocompatibility.
For this purpose, surface modified and exfoliated layered
gadolinium hydroxide nanoparticles were developed for use as
multimodal contrast agents for MRI and fluorescence imaging.108
In this material, LDH nanoparticles contain MR-active Gd3+ ions,
which makes the material have potential for MRI. Then LDH
nanoparticles were exfoliated by incorporation of long chain oleate
ions, as shown in Fig. 9a. The separate individual layers were
coated with phospholipids with poly(ethylene glycol) tail groups
and fluorescent molecules to achieve multimodal imaging (MRI +
fluorescence imaging) application in vivo (Fig. 9a). In another
work, LDH nanoparticles were coated with liposome, enabling
excellent water dispersion and sustained release characteristic, as
shown in Fig. 9b.109 Recently, the bovine serum albumin (BSA) pre-
coating strategy was introduced to increase LDH nanoparticles’
stability in buffered solution. This coating strategy could substan-
tially prevent aggregation of LDH nanoparticles, and increase their
cellular uptake in Chinese hamster ovary cells.110 Shi et al.
fabricated bivalent cation 64Cu2+ and trivalent cation 44Sc3+
labelled LDH nanoparticles-BSA nanoparticles with excellent
labelling efficiency and stability for in vivo positron emission
tomography (PET).111 In this work, PET imaging showed that
prominent tumor uptake was achieved in 4T1 breast cancer with
64Cu-LDH nanoparticles-BSA via passive targeting alone (7.7 
0.1% ID g1 at 16 h post-injection; n = 3). Zuo et al. modified
LDH nanoparticles with brain tumor targeting ligands
angiopep-2 and rabies virus glycoprotein.112 The ligands were
first covalently linked with BSA through the heterobifunctional
cross-linker sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-
1-carboxylate, and then coated onto the surface of LDH nano-
particles through electrostatic interaction, followed by cross-linking
with the cross-linker glutaraldehyde to immobilize these BSAs
on the LDH nanoparticles’ surface. The ligand conjugated LDH
nanoparticles showed dramatically enhanced cellular uptake by
Fig. 7 (A) Strategic overview of a cisplatin-loaded nanohybrid for immuno-
chemotherapy. The nanohybrid PtIV-IDOi/LDH enters cancer cells and
releases the PtIV prodrug and IDOi. The former is reduced to cisplatin that
binds to genomic DNA to induce cancer cell apoptosis; simultaneously, the
latter blocks the pathway to produce kynurenine, leaving more tryptophan in
the microenvironment for T cell proliferation and development. With the
checkpoint inhibitor IDOi, proliferated T cells can distinguish cancer cells
through the signal from antigen presenting cells (APC, such as dendritic cells),
and enhance the chemotherapy. At last, the nanohybrid elevates cancer cell
cycle arrest and apoptosis. IDO = indoleamine-2,3-dioxygenase, TCR = T cell
receptor, MHC = major histocompatibility complex, Trp = tryptophan,
Kyn = kynurenine. (B) The growth of HeLa tumors in a xenograft model
with various treatment groups indicated. PBMCs (5  106 cells per mouse)
were injected intravenously on Day 0. BSA-coated PtIV–IDOi (1 : 40)/LDH
([Pt] = 0.5 mg kg1) was injected for 4 times. The tumor volume of each
group was measured every two days for 14 days of duration. *p o 0.05,
***p o 0.001, Student’s t-test. Mean  SD, n = 5.97 (Reproduced from
Wiley-VCH Verlag GmbH & Co. KGaA with permission.)
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brain tumor cells, and increased the delivery efficacy of 5-FU for
effective inhibition of neural U87 and N2a cells.
In addition to the above surface coating method which is
mostly via electrostatic attraction, another approach is to
modify LDH nanoparticles through covalent bonding by making
use of the –OH functional groups on the surface. Park et al.
introduced (3-aminopropyl)triethoxysilane (APTES) to tailor
LDH nanoparticles through condensation between the hydroxyl
groups of LDH and the ethoxy groups of APTES molecules to
form a covalent bond.113 With this method, amine groups were
grafted on the surface and interlayer spacing of LDH nano-
particles, making it convenient to attach other guest molecules. For
example, the cancer cell specific ligand folic acid and fluorescein-5-
isothiocyanate (FITC) were successfully conjugated onto the surface
Fig. 8 Schematic illustration of (a) the synthetic procedure and (b) structure related multifunctional properties of Mn-LDH nanoparticles.102
(Reproduced from Wiley-VCH Verlag GmbH & Co. KGaA with permission.)
Fig. 9 The surface modification approach for the fabrication of (a) exfoliated layered gadolinium hydroxide108 (reproduced from Wiley-VCH Verlag
GmbH & Co. KGaA with permission) and (b) liposome coated LDH109 (reproduced from Elsevier with permission).
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of amine-modified LDH nanoparticles through connection with
amine functional groups.114 Folic acid conjugated LDH nano-
particles showed greatly enhanced selectivity to folate receptor
over-expressing cells (KB cells).114 Wei et al. incorporated a near-
infrared (NIR) dye into amine-modified LDH nanoparticles by
electrostatic attraction, and further coated themwith chitosan using
glutaraldehyde as a cross-linking agent. These chitosan coated LDH
nanoparticles had minimal cytotoxicity.115 The subsequent in vivo
application demonstrated the potential application of chitosan
coated LDH nanoparticles for imaging.115 Covalent conjugation of
Cy5.5 molecules and Polyethylene glycol (PEG)-5000 to amine
modified LDH nanoparticles was also reported, and LDH-PEG-
5000 showed an enhanced blood circulation time without high
fluorescence intensity in the major organs.116 Yan et al. developed
an approach to exfoliate LDH nanoparticles to thin individual layers
so that it is possible to modify both sides of hydroxide nanosheets
which are much thinner than conventional LDH nanoparticles.
These exfoliated LDH thin layers could be linked with APTES-folic
acid and these nanostructures were able to self-assemble into
nanoclusters.117,118 Through this approach, folic acid modified
LDH nanoparticles were prepared for targeting cancer cells with
folate receptor overexpression. Folic acid modified LDH nano-
particles possessed a high drug loading capacity of 27 wt% and
dramatically improved the therapeutic efficacy of MTX.117 A similar
approach was also used to modify LDH nanoparticles with
fluorescein molecules.118 Attractively, this method produced
LDH-fluorescein nanoparticles with a very high quantum yield
(QY) of 55.1%. This is significantly better than those prepared
through the previously reported anion exchange (3.0%) and
coprecipitation (12.4%) approaches. Moreover, this type of
LDH-fluorescein nanoparticles showed strong fluorescence even
in a solid state, while conventional dye molecules completely
lost fluorescence in a dry form due to concentration quenching.
These nanostructures were also capable of self-assembling into
a transparent, free-standing and fluorescent film.118 Recently,
Park et al. reported biodegradable LDH nanoparticles for active
tumor targeting in siRNA transportation. In this work, folic acid
conjugated LDH nanoparticles showed 3.0-fold higher suppres-
sion of tumor volume than the non-modified LDH system119
(Fig. 10). Consistent with the improved siRNA delivery, a low
level of Survivin protein and proliferating cell nuclear antigen
(PCNA) in tumors was detected in the LDH-folic acid treated
group. The results revealed that folic acid modified LDH nano-
particles loaded with siRNA efficiently suppressed Survivin
expression at both post-transcriptional and translational levels
and induced necrosis in cancer cells.
Recently, it was reported that photosensitizer Ce6 could be
covalently conjugated to PEG modified LDH nanoflakes.120 In
this study, Ce6 molecules were firmly anchored to the stabilized
LDH nanoflakes and showed very slow release profiles of Ce6,
avoiding premature release of drug molecules in blood and
ensuring their efficient delivery to tumors. It was found that
LDH nanoparticles–Ce6 significantly inhibited tumor growth as
indicated by the size reduction to 13.4%, 14.3% and 26.9% of the
tumor volume in the PBS, LDH–Ce6 Mix, and free Ce6 treated
groups, respectively. In addition, LDH could be exfoliated to
ultrathin nanosheets with a size of 50 nm and a thickness of
about 1.4–4 nm.121 The fabricated nanosheets were tested for
delivery of a negatively charged anticancer drug, MTX, in a mouse
model, which demonstrated dramatically improved therapeutic
efficacy, indicated by the effective inhibition of tumor growth
with minimal side-effects. In comparison, if using the conven-
tional non-surface modified LDH nanoparticles for delivery of
MTX, the tumor inhibition efficacy is similar to that of free MTX
molecules. Also importantly, with covalent conjugation, LDH
nanostructures can not only load negatively charged species like
conventional LDH nanoparticles, but also neutral molecules such
as PEG and positively charged rhodamine B dyes.
4. LDH nanocomposites for
biomedical applications
With the rapid development of LDH nanostructures, extensive
research has also been extended to incorporating them with a
spectrum of other materials to further broaden their applications.
LDH based nanocomposites possess not only advantages and
merits of LDH but also those of the combined materials.
Therefore, the composites have the potential to satisfy advanced
requirements of many practical utilizations.122 Next, the bio-
medical and healthcare applications of LDH nanocomposites
will be summarized.
4.1 Nanocomposites with LDH as the core
Silica coating is one of the most commonly used methods to
coat nanoparticles because of its ease of further functionalization,
optical transparency, good hydrophilicity, excellent stability and
high biocompatibility.123–128 Therefore, LDH nanoparticles were
also decorated with a silica shell, using tetraethyl orthosilicate
Si(OC2H5)4 (TEOS) as a silica source.
122 Initially, a surfactant
template method was reported for an efficient synthesis of an
LDH@SiO2 nanocomposite (Fig. 11a). In the method, CTAB
was used as a surfactant-template to fabricate the LDH@SiO2
nanocomposite. The obtained nanostructures had uniform and
accessible mesopores (B2.2 nm), high surface area (B430 m2 g1),
and large pore volume (B0.22 cm3 g1). This nanocomposite was
tested for a slow release of ibuprofen.129 Then surfactants FC4 and
F127 were also introduced to synthesize the LDH@SiO2 nano-
composite for sustained and pH sensitive release130 (Fig. 11b).
Li et al. used well-dispersed amine-functionalized SiO2 nanodots
to coat LDH by electrostatic interaction followed by condensation of
APTES11 (Fig. 11c). These LDH-SiO2 dot nanostructures were well
dispersible in cell culture medium and PBS buffer, and could be
used to effectively deliver siRNA into U2OS cells.11 Besides silica
coating, a Gd-doped LDH@Au nanocomposite was fabricated for
drug delivery and diagnosis.9 This nanocomposite system displayed
high DOX loading capacity, and enabled a pH sensitive release
profile of DOX. The Gd-doped LDH@Au nanocomposite was able to
efficiently deliver DOX into cells, release DOX in the cytoplasm, and
ultimately cause cancer cell death.9 Meanwhile, with Gd and Au
doping, this nanocomposite could be employed for in vitro
Computed Tomography (CT) and T1-weighted MR imaging, with
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a better performance than commercial MRI and CT contrast
reagents and negligible cytotoxicity. A luminescent Eu-doped
LDH nanocomposite was also synthesized with magnetic
Fe3O4 nanoparticle coating.
131 This LDH could load 31% (w/w)
ibuprofen and exhibited sustained release.131
4.2 Nanocomposites with LDH as the shell
A LDH based nanocomposite structure was designed using
magnetic nanoparticles and LDH as the core and shell, respectively.
This structure was fabricated with a simple one-step co-precipitation
method.132,133 Very attractively, it was explored that a greatly
decreased drug release rate of diclofenac and ibuprofen was
achieved when the composite structure was placed under a
magnetic field. Thismagnetic field controlled ‘‘on–off’’ phenomenon
is due to the instant aggregation of the magnetic nanocomposite
induced by an external magnetic field.132,133 This structure was
then continued to be developed for cancer therapy.134,135 In one
representative study, the anticancer agent doxifluridine was
loaded to monodispersed strongly magnetic Fe3O4@LDH nano-
structures. This Fe3O4@LDH nanocomposite had a well-defined
core–shell structure, strong magnetization and magnetic guided
controlled release properties.123 For drug delivery, carboxyl
group modified DOX was loaded to the LDH shell via anion-
exchange135 (Fig. 12). This DOX-COOH loaded nanocomposite
exhibited high cytotoxicity and powerful inhibition towards
cancer cells (HeLa cells), but had low toxicity to normal cells
(HEK 293T Cells). The mechanism may be explained as follows:
the acidic cytoplasm of HeLa cells stimulated rapid degradation
of the LDH shell and converted DOX-COOH to positively
charged DOX, thereby rapidly escaping from the positively
Fig. 10 In vivo anti-tumor effect and Survivin down-regulation in tumors treated with each sample through the IP route once every 7 days. (A) Tumor
growth inhibition (n = 6 per group). Tumor volumes were measured at 2-day intervals. Tumor sizes are presented as means  SE. *po 0.05 versus LDH/
siSurvivin treated group; ** p o 0.01 versus PBS-treated group (the inset shows the mice 18 days post-treatment. The tumor growth rate with LDHFA/
siSurvivin was significantly slower, resulting in a tumor volume of 583 mm3, which was remarkably smaller than the values in other groups: 1693 mm3
(PBS); 1474 mm3 (siSurvivin); 1157 mm3 (LDH/siSurvivin)). (B) H&E, Survivin protein and PCNA stained tumor tissue section (n = 3 per group) (original
magnification: 100).119 (Reproduced from Wiley-VCH Verlag GmbH & Co. KGaA with permission.)
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charged intercalation of the LDH shell by strong repulsive
interaction, but the relatively neutral cytoplasm of HEK 293T
cells caused a smaller amount of DOX to be released.135 In
addition to anticancer therapy, this type of magnetic nanoparticles@
LDH nanocomposite was also used for separation of proteins.136
Nanostructures with a SiO2-coated Fe3O4 magnetite core and a LDH
shell were synthesized by an in situ growthmethod (Fig. 13a). The as-
fabricated nanocomposite was 600 nm in diameter, and had a large
surface area (83 m2 g1) and uniform mesochannels (4.3 nm)
(Fig. 13b and c). The nanocomposite effectively and selectively
separated histidine-tagged green fluorescent protein with a
binding capacity of 239 mg mg1, and remained stable in several
separation cycles136 (Fig. 13d).
SiO2 nanostructures were also encapsulated with a LDH
shell. A 210 nm SiO2@LDH core–shell nanocomposite was
designed to enhance the immune adjuvant activity.137 The zeta
potential of this core–shell structure was 0.521 mV, making it
easier for DNA binding compared with naked SiO2 nanostructures
which were negatively charged. The larger surface area of this
nanocomposite can load a relatively large amount of DNA vaccine.
Moreover, the SiO2@LDH nanocomposite protected DNA from
degradation, increased transfection efficiency, and efficiently
promoted macrophage activation, compared with SiO2 and LDH
Fig. 12 (a) The plausible DOX release mechanism of DOX@MSPs/Ni-
LDH-folate in the cytoplasm of tumor cells (acidic environment). (b) The
different fluorescence behaviors of HeLa and HEK 293T cells incubated
with nano-drugs. (c) The mechanism of pumping positively charged DOX
out of the LDH sheets.135 (reproduced from Elsevier with permission).
Fig. 11 Schematic illustration of the preparation of LDH core and silica
shell nanocomposites11,129,130 (reproduced from The Royal Society of
Chemistry and Springer with permission).
Fig. 13 (a) Schematic illustration of the fabrication of the Fe3O4@SiO2@
LDH nanocomposite; (b and c) TEM (b) and SEM (c) images of the
Fe3O4@SiO2@NiAl-LDH nanocomposite; (d) photographs of separation
of His-tagged GFP by Fe3O4@SiO2@NiAl-LDH microspheres after different
times136 (reproduced from American Chemical Society with permission).
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alone.137 The in vivo immunization study showed that this kind
of DNA vaccine loaded SiO2@LDH nanocomposite induced
higher serum antibody response and also promoted T-cell
proliferation and skewed T helper cells toward Th1 polarization.137
Later on, a similar structure of SiO2@LDH nanocomposite was used
to deliver Newcastle disease virus DNA vaccine.138 The composite
structure possessed a great loading capacity of 39.66%, and led to
increased in vitro gene transfection efficacy, and strong cellular,
humoral and mucosal immune responses by intranasal immu-
nization of specific pathogen-free chickens.138 Additionally, the
SiO2@LDH nanocomposite was designed for controlled release.
Mesoporous silica was used as a core material to load guest
molecules of (Ru(bpy)3Cl2) followed by encapsulation of LDH
nanosheets via electrostatic adsorption139 (Fig. 14). This nano-
composite was used for pH-responsive controlled release by
dissolution of the LDH coating in an acidic environment to
trigger the release of the drug from mesoporous silica nano-
particles: almost no (Ru(bpy)3Cl2) release was found from the
SiO2@LDH nanocomposite in the physiological environment
(pH = 7.4), while slow and fast release took place at pH = 4.0/5.0
and pH = 3.0, respectively (Fig. 14a). Moreover, a multifunctional
Y2O3:Er
3+,Yb3+@SiO2@LDH nanocomposite system was fabricated
for simultaneous tumor optical imaging and therapy.140 LDH
nanosheets were deposited on the surface of monodispersed SiO2
coated Y2O3:Er
3+,Yb3+ nanoparticles by precipitation followed by
hydrothermal treatment.140 In this system, Y2O3:Er
3+,Yb3+ nano-
particles worked as a near infrared fluorescent nanophosphor which
exhibited strong red upconversion fluorescence under 980 nm laser
irradiation. The positively charged surface of LDHwas utilized as an
anticancer drug nanovehicle for efficient intracellular delivery.140
Au nanoparticles have also been employed as a core material,
wrapped with LDH. In this work, MTX was first attached to citrate-
stabilized Au nanoparticles; then, a SiO2 layer was decorated on
the surface of the Au nanostructure using tetraethyl orthosilicate
(TEOS) as a silica source; later, NaOH was added to the SiO2 shell;
and finally, Mg2+ and Al3+ were added to the solution to obtain a
LDH shell.141 By controlling the pH of SiO2 etching, a core/shell
structure (pH 11) or a york/shell structure (pH 10.5) was able to
be controllably synthesized. MTX loaded to this nanostructure
exhibited better anticancer efficiency, compared with free MTX
and LDH-MTX.
4.3 LDH thin film coating
LDH based film coating has been widely used for antimicrobial,
sensing, electrochemical and optical applications.142–148 In a
typical work, substrates including metals, ceramics, and glass
were coated with oriented LDH films with strong adhesion.
Subsequently, silver ions were in situ reduced to metallic silver
nanoparticles and evenly distributed on the LDH surface149
(Fig. 15a and b). The Ag-LDH coating showed excellent and
durable antimicrobial activities against both Gram-negative
(E. coli and P. aeruginosa) and Gram-positive (B. subtilis and
S. aureus) bacteria149 (Fig. 15c–g). Ciprofloxacin loaded LDH
was also coated on a middle ear prostheses implant to combat
Fig. 14 (a) Synthesis procedure of MSN–Ru@LDH and the pH-responsive
controlled release mechanism; (b) TEM images of (A) MSNs and (B) MSN–
Ru@LDH (MSN–Ru: Ru(bpy)3
2+ loaded mesoporous silica nanoparticles).139
(Reproduced from Royal Society of Chemistry with permission.)
Fig. 15 (a) SEM image of Ag-LDH, (b) TEM image of Ag-LDH coating
scraped from the substrate. (c and d) Bacterial growth curves of (c) E. coli
and (d) B. subtilis in Luria-Bertani broth in the presence of the glass
substrate, LDH coating and Ag-LDH coating on the glass substrates.
(e–g) Confocal microscopy images of E. coli on the surface of (e) glass,
(f) LDH coating, and (g) Ag-LDH coating after 24 h of culture (live cells
stained green).149 (Reproduced fromWiley-VCH Verlag GmbH & Co. KGaA
with permission.)
Review Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
A
ug
us
t 2
01
9.
 D
ow
nl
oa
de
d 
on
 9
/1
9/
20
19
 3
:1
1:
01
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2019 J. Mater. Chem. B
infection with P. aeruginosa.150 The film displayed excellent
activity against infection immediately after implantation, also
with persisting attenuated activity when re-infection was triggered
at 1 week after surgery.150 Similar techniques were as well applied
to decorate porous titanium implants with antibiotics for pro-
longed antibiotic release, improved cell adhesion and good in vitro
and in vivo antibacterial effects.151 It was found that middle ear
prostheses coated with LDH showed little signs of degradation
after being implanted into the middle ear of rabbits for 10 days,
indicating that the LDH has excellent biocompatibility and
stability in the middle ear.152 Moreover, Peng et al. reported
Mg–Al LDH and Mg(OH)2 co-coated Mg–Nd–Zn–Zr alloy to
improve its corrosion resistance and biocompatibility.153 The
LDH coated alloy also showed greatly enhanced cell adhesion,
migration and proliferation and a decreased hemolysis ratio to a
level suitable for clinical application. The in vivo study demon-
strated that the Mg(OH)2 and Mg–Al LDH coating exhibited
better histocompatibility than pure Mg(OH)2 coatings or untreated
magnesium alloy.
4.4 Other types of LDH based composites
As a ceramic material, LDH has superior mechanical, optical
and thermal properties which pure polymers normally lack.154–157
Taking advantage of these merits, LDH nanoparticles can be
regarded as a filler to incorporate into the polymer matrix to form
nanocomposites and thus improve the desirable property of a pure
polymer matrix.158–162 In one application, LDH nanoparticles were
added to carboxymethylcellulose (CMC) to fabricate mechanically
strengthened dissolvable polymer microneedles for improved
transdermal delivery to human skin.163 The addition of LDH
nanoparticles dramatically improved the mechanical property
of weak dissolving polymers: the elastic modulus of CMC was
measured to be 0.993  0.065 and 2.878 0.123 GPa before and
after the addition of 5 wt% LDH to CMC (Fig. 16a). With the
improved mechanical strength, LDH-CMC microneedles could
penetrate pig and human skin much more uniformly, also with
a substantially greater penetration depth than CMC micro-
needles (Fig. 16b and c). The advantage of this mechanically
strengthened LDH-CMC nanocomposite is that it still dissolves
very rapidly within the skin (Fig. 16d and e), while previously
reported mechanically strengthened microneedles suffer from
slower dissolution rates, which can affect their clinical use as
dissolvable microneedles.163–165
In addition, Mg–Al LDH nanoparticles were added to chit-
osan to fabricate a porous scaffold and loaded with Pifithrin-a
(PFTa) to enhance stem cell osteogenic differentiation and
bone regeneration.166 PFTa molecules exhibit a potent ability
to induce osteogenesis of hBMSCs via the GSK3b/b-catenin
pathway. Here the LDH-CS-PFTa scaffold was demonstrated
to significantly enhance the osteogenic differentiation of
hBMSCs. When used in an in vivo test, the scaffold greatly
increased the repair and regeneration of bone tissue in cranial
defect model rats in comparison with that in the control rats at
12 weeks post-implantation. Thus, the development of a LDH-
chitosan based scaffold provided a promising strategy for tissue
engineering applications. Recently, a bone remodeling drug,
risedronate (RS), was loaded into LDH nanoparticles, followed
by the formation of a sheet with poly(lactic-co-glycolic acid) on a
clinically approved bioabsorbable bone plate (Fig. 17).167 In this
design, the presence of metals in LDH enabled in vivo X-ray images
for up to 4 weeks after implantation. In themeantime, the sustained
release of drug greatly improved bone regeneration.167
5. Discussion
5.1 Advantages of LDH nanostructures
LDH nanostructures have been extensively studied for about
20 years with constantly increasing interest as indicated in the
introduction. For biomedical applications, LDH nanostructures
offer many advantages. First, these nanostructures possess pH
sensitivity. LDH nanostructures are made of hydroxides, making
them sensitive to acidic environments with very good bio-
degradability. This enables LDH nanostructures to be ideal for
cancer therapy as tumor tissues and cancer cells possess lower
pH. Using pH as a stimuli has constantly been a popular strategy
for controlled drug delivery and release. Biodegradability is
also very important for body clearance of the material and
consequently for enhancing biocompatibility and safety
profile.168 Second, the metal component of LDH nanostructures
could be easily tuned for different applications.169–171 For the
consideration of biocompatibility, metal ions like Zn2+, Mg2+ and
Al3+ are the typical candidates for divalent and trivalent metal
cations, respectively. Other types of metal ions like Mn2+ can also
Fig. 16 (a) Load–displacement curves of pure sodium carboxymethylcellu-
lose (CMC) and CMC with LDH fillers; (b) fabricated dissolving polymer
microneedles (inset: digital camera image of a polymer microneedle array);
(c) reflectance confocal microscopy images of pig skin after 5 min CMC–LDH
nanocomposite microneedle application; (d and e) merged fluorescence and
reflectance confocal microscopy images of CMC–LDH nanocomposite
microneedles: (d) before application and (e) 5 min after application to pig
skin.163 (Reproduced from Wiley-VCH Verlag GmbH & Co. KGaA with
permission).
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be incorporated for MRI observation. Compared with other
materials such as semiconductor quantum dots for fluorescence
imaging, MRI is much more clinically relevant.172 Third, LDH
nanostructures are competent for cell membrane penetration
due to their positive charge, thereby greatly improving intracellular
delivery efficacy. Biological barriers are the major obstacles of
effective delivery of drugs, genes and biomolecules into the cell
cytoplasm.173,174 Fourth, the drug loading process can be very
straightforward in the case of negatively charged species and the
drug loading capacity is relatively high. Fifth, the fabrication is
cheap and the size tunability can vary with a wide range from
20 nm to 10 mm, suitable for different biological and clinical
applications. This size tunability is far greater than for most other
types of nanomaterials. Sixth, our research showed that ultra-thin
LDH nanosheets tend to preferably accumulate in the kidney
instead of liver like most other nanomaterials.121 This may be
good for subsequent clearance and more suitable for clinical
applications.175,176 Seventh, LDH has a great flexibility to form
numerous types of composites for various utilizations. Further-
more, LDH is a type of ceramic nanoparticles with very high
mechanical strength and therefore can be utilized as a filler to
modify the mechanical strength of a polymer matrix for specific
applications and also as a thin film coating on various kinds of
implantation devices.
5.2 Challenges of LDH nanostructures for biomedical
applications
Although LDH nanostructures possess superior advantages that
seem very promising for future applications, several challenges
are still remaining. For example, because of the positive charge
of LDH nanostructures, they may interact with negatively
charge biomolecules in the biological environment and lead to
loss of surface charge and aggregation. This challenge becomes
crucial when LDH nanostructures are administrated via the
blood system. Therefore, improvement of the stability of LDH
nanostructures is a major challenge. Second, compared with
other nanomaterials, there is less flexibility in functionalizing
the surface of LDH nanostructures. For conventional LDH nano-
particles, due to the bulky thickness, the surface modification of
the 2 outermost LDH layers is not enough for high stability in the
biological environment. Therefore, it is important to develop new
generations of ultra-thin LDH nanosheets with flexibility of sur-
face modification for practical applications. Third, in comparison
with other inorganic materials such as silica and gold nano-
particles, the controllability of the fabrication of LDH nano-
structures and the reproducibility need to be substantially
improved. To tackle this issue, continuous synthesis has been
employed instead of the traditional flow chemistry approaches
that allow reducing the residence time and maintaining almost
constant supersaturation to produce LDH in large amounts.177
6. Conclusions and future outlook
This review summarizes the development of LDH nanomaterials
including pristine LDH nanostructures, surface modified LDH
nanostructures, and LDH based nanocomposites for biomedical
applications. LDH shows good biocompatibility, pH sensitivity,
biodegradability, high intracellular delivery efficacy, and great
flexibility in size tunability and nanocomposite formation. Initially,
pristine LDH nanostructures were used for drug and gene delivery
and photodynamic therapy. Although effective, it is desirable to
surface modify these LDH nanostructures for improved properties
due to the importance of the surface of nanomaterials. Surface
modification not only makes LDH nanostructures more stable in
buffer solution and blood system, but also enables versatile
functions such as targeted delivery. Beyond using LDH nano-
structures alone, there is great flexibility to combine LDH with
many other materials such as metals, metal oxides, and poly-
mers to further extend their functions and applications. It is
expected that LDH nanomaterials have great potential in clinical
applications due to their unique characteristics. In the future, the
following aspects need to be explored to facilitate the application
of LDH nanomaterials and their potential commercial use in the
clinic. Firstly, it is essential to improve the synthesis approaches
to produce highly uniform and reproducible LDH nanostructures
with small variation in size, thickness, and geometry. Secondly,
surface modification and drug loading under mild conditions
Fig. 17 Schematic preparation process of a theranostic plate. (A) RS-LDH
sheets were separately prepared using polydimethylsiloxane (PDMS) molds
consisting of square-shaped frames filled with a paste of RS-LDH and
PLGA (5 : 1, w/w). (B) PLGA solution was sprayed onto the surface of a bone
plate, and (C) the RS-LDH sheet was attached to the top to produce (D) the
theranostic bone plate. (E) Optical images of the bioabsorbable bone
fixation plates with and without a theranostic RS-LDH sheet. (F) FE-SEM
image of the surface of a theranostic RS-LDH sheet. (G) In vitro drug-
release profiles of the intact RS, RS-LDH, RS-LDH_P1, and RS-LDH_P2 in
PBS (pH 7.4). (H) Representative in vitro X-ray images and (I) densitometry
measurements of LDH_P2, RS-LDH_P1, and RS-LDH_P2 over 42 d.
*RS-LDH_P1 differs significantly from both LDH_P2 and RS-LDH_P2
(p o 0.05).167 (Reproduced from Wiley-VCH Verlag GmbH & Co. KGaA
with permission.)
Review Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
A
ug
us
t 2
01
9.
 D
ow
nl
oa
de
d 
on
 9
/1
9/
20
19
 3
:1
1:
01
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2019 J. Mater. Chem. B
need to be established to ensure improved properties and
minimize the influence of drug loading conditions such as
temperature, time and pH on loaded drugs and genes. Thirdly,
it is required to fabricate highly stable LDH nanomaterials in
biological solution so that the drug delivery system can efficiently
transport drugs and genes to target sites with minimal pre-mature
drug and gene release. The high stability will prevent aggregation of
nanostructures which can result in low therapeutic efficacy and
possible precipitation in blood circulation. In this regard, it is
desirable to develop ultra-thin LDH nanosheets. Fourthly, it is
needed to thoroughly understand the in vivo biodegradability,
biodistribution, and clearance of LDH nanomaterials. Fifthly, the
flexibility of formation of LDH nanocomposites is an important
advantage of LDH. This area of research should be significantly
expanded, particularly by combining with materials which can
circumvent the limitation of LDH nanostructures or enhance
properties and performance. Moreover, there are many other types
of nanostructures for biomedical applications such as bioceramic
nanoparticles. However, there is a lack of studies that compare
different types of nanomaterials with the same standard protocols
for direct comparison so it is difficult to identify the best candidate
for practical applications.
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